IL20RB

Summary

IL20RB (interleukin 20 receptor subunit beta, HGNC:6004) is a protein-coding gene on chromosome 3q22.3, encoding Interleukin-20 receptor subunit beta (Q6UXL0). The IL20RA/IL20RB dimer is a receptor for IL19, IL20 and IL24.

IL20RB and IL20RA (MIM 605620) form a heterodimeric receptor for interleukin-20 (IL20; MIM 605619) (Blumberg et al., 2001 [PubMed 11163236]).

Source: NCBI Gene 53833 — RefSeq curated summary.

At a glance

• GWAS associations: 16
• Clinical variants (ClinVar): 48 total — 1 likely-pathogenic
• MANE Select transcript: NM_144717

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6004
Approved symbol	IL20RB
Name	interleukin 20 receptor subunit beta
Location	3q22.3
Locus type	gene with protein product
Status	Approved
Aliases	DIRS1, IL-20R2, MGC34923
Ensembl gene	ENSG00000174564
Ensembl biotype	protein_coding
OMIM	605621
Entrez	53833

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 nonsense_mediated_decay, 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000329582, ENST00000469964, ENST00000475972, ENST00000484501, ENST00000491483, ENST00000907829

RefSeq mRNA: 1 — MANE Select: NM_144717 NM_144717

CCDS: CCDS3093

Canonical transcript exons

ENST00000329582 — 7 exons

Exon	Start	End
ENSE00002319447	136957983	136958201
ENSE00002319932	136980466	136980592
ENSE00003462120	136989441	136989565
ENSE00003546290	136995414	136995556
ENSE00003615935	136991938	136992088
ENSE00003630967	137010113	137011085
ENSE00003660567	136982160	136982350

Expression profiles

Bgee: expression breadth ubiquitous, 180 present calls, max score 99.50.

FANTOM5 (CAGE): breadth broad, TPM avg 5.9732 / max 406.7284, expressed in 489 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
38756	4.5047	443
38755	0.9018	227
38757	0.3069	137
38758	0.1246	69
202943	0.0748	42
202942	0.0603	30

Top tissues by expression

250 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	99.50	gold quality
lower esophagus mucosa	UBERON:0035834	99.25	gold quality
skin of abdomen	UBERON:0001416	97.77	gold quality
upper leg skin	UBERON:0004262	97.61	gold quality
skin of leg	UBERON:0001511	97.55	gold quality
zone of skin	UBERON:0000014	97.47	gold quality
penis	UBERON:0000989	96.93	gold quality
esophagus mucosa	UBERON:0002469	96.89	gold quality
skin of hip	UBERON:0001554	96.71	gold quality
gingival epithelium	UBERON:0001949	96.61	gold quality
gingiva	UBERON:0001828	96.50	gold quality
mammalian vulva	UBERON:0000997	95.07	gold quality
esophagus squamous epithelium	UBERON:0006920	94.93	gold quality
pharyngeal mucosa	UBERON:0000355	94.21	gold quality
nipple	UBERON:0002030	93.79	gold quality
oral cavity	UBERON:0000167	92.13	gold quality
vagina	UBERON:0000996	90.09	gold quality
nasal cavity epithelium	UBERON:0005384	89.37	gold quality
buccal mucosa cell	CL:0002336	85.91	gold quality
body of tongue	UBERON:0011876	83.79	gold quality
esophagus	UBERON:0001043	82.86	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	81.25	gold quality
tibial nerve	UBERON:0001323	81.17	gold quality
nasal cavity mucosa	UBERON:0001826	80.39	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.42	silver quality
mouth mucosa	UBERON:0003729	77.24	gold quality
palpebral conjunctiva	UBERON:0001812	77.19	gold quality
epithelium of nasopharynx	UBERON:0001951	76.58	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	76.42	gold quality
tongue	UBERON:0001723	75.00	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

30 targeting IL20RB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-511-3P	99.99	68.85	1467
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-6887-3P	99.66	67.83	1778
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-573	99.55	67.44	955
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-5589-3P	99.29	68.30	1443
HSA-MIR-223-5P	99.24	68.82	1206
HSA-MIR-6876-3P	98.97	65.69	765
HSA-MIR-626	98.89	66.21	762
HSA-MIR-374B-3P	98.63	68.24	1360
HSA-MIR-6826-3P	98.19	66.32	1153
HSA-MIR-3155A	98.16	66.09	965
HSA-MIR-3155B	98.16	66.09	965
HSA-MIR-484	98.16	66.92	1074
HSA-MIR-6870-3P	98.08	65.10	692
HSA-MIR-4494	97.86	64.93	850
HSA-MIR-6765-3P	97.83	64.59	1165
HSA-MIR-4314	97.50	67.30	1369
HSA-MIR-6781-3P	97.44	66.85	970
HSA-MIR-6851-3P	95.73	65.11	688
HSA-MIR-7109-3P	94.23	67.19	743

Literature-anchored findings (GeneRIF, showing 7)

• forms stable complex with interleukin-19 and interleukin-20 [IL-20R1][IL-20R2] (PMID:14580208)
• The hypotheses that genetic variations of the IL-20-RI influence susceptibility to psoriasis and single nucleotide polymorphisms (SNPs) in the IL20RA and IL20RB genes in psoriasis patients were investigated. (PMID:18480827)
• Complete mda-7/IL-24 receptors (IL-22R1/IL-20R2 and IL-20R1/IL-20R2) are seldom expressed in liver cancer cell lines. (PMID:19666410)
• crystallographic asymmetric unit contains one IL-20-IL-20R1-IL-20R2 complex, corresponding to a solvent content of approximately 54% (PMID:22232181)
• The crystal structure of the IL-20/IL-20R1/IL-20R2 complex reveals how type I and II complexes discriminate cognate from noncognate ligands (PMID:22802649)
• Trabecular meshwork cells express IL-20 receptors; Mutation of the T104 residue in IL-20R2 leads to a reduction in STAT3 phosphorylation as well as decreased matrix metalloproteinase activity (PMID:24455976)
• Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma. (PMID:35883015)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il20rb	ENSMUSG00000044244
rattus_norvegicus	Il20rb	ENSRNOG00000023214

Paralogs (11): IL20RA (ENSG00000016402), IFNGR1 (ENSG00000027697), IL10RA (ENSG00000110324), F3 (ENSG00000117525), IFNAR1 (ENSG00000142166), IL22RA1 (ENSG00000142677), IFNAR2 (ENSG00000159110), IFNGR2 (ENSG00000159128), IL22RA2 (ENSG00000164485), IFNLR1 (ENSG00000185436), IL10RB (ENSG00000243646)

Protein

Protein identifiers

Interleukin-20 receptor subunit beta — Q6UXL0 (reviewed: Q6UXL0)

Alternative names: Fibronectin type III domain containing 6, IL-20R2

All UniProt accessions (4): Q6UXL0, F8WAV8, F8WC67, H7C5S5

UniProt curated annotations — full annotation on UniProt →

Function. The IL20RA/IL20RB dimer is a receptor for IL19, IL20 and IL24. The IL22RA1/IL20RB dimer is a receptor for IL20 and IL24.

Subunit / interactions. Heterodimer with IL20RA and heterodimer with IL22RA1.

Subcellular location. Membrane.

Tissue specificity. Widely expressed with highest levels in skin and testis. Highly expressed in psoriatic skin.

Similarity. Belongs to the type II cytokine receptor family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q6UXL0-1	1	yes
Q6UXL0-3	2

RefSeq proteins (1): NP_653318* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003961	FN3_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR015373	Interferon/interleukin_rcp_dom	Domain
IPR036116	FN3_sf	Homologous_superfamily
IPR050650

Pfam: PF01108, PF09294

UniProt features (33 total): strand 15, splice variant 3, helix 3, disulfide bond 2, topological domain 2, domain 2, glycosylation site 2, signal peptide 1, chain 1, transmembrane region 1, turn 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
6DF3	X-RAY DIFFRACTION	2.15
4DOH	X-RAY DIFFRACTION	2.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6UXL0-F1	83.91	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 202–223, 89–97

Glycosylation sites (2): 40, 134

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-8854691	Interleukin-20 family signaling

MSigDB gene sets: 164 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_DENDRITIC_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_INFLAMMATORY_RESPONSE_TO_ANTIGENIC_STIMULUS, GOBP_NEGATIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_INTERLEUKIN_4, GOBP_RESPONSE_TO_PEPTIDE, GOBP_NEGATIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_NEGATIVE_REGULATION_OF_LEUKOCYTE_MEDIATED_IMMUNITY, GOBP_NEGATIVE_REGULATION_OF_CELL_CELL_ADHESION

GO Biological Process (14): negative regulation of type IV hypersensitivity (GO:0001808), inflammatory response to antigenic stimulus (GO:0002437), immune response-inhibiting signal transduction (GO:0002765), cytokine-mediated signaling pathway (GO:0019221), negative regulation of type II interferon production (GO:0032689), negative regulation of interleukin-2 production (GO:0032703), positive regulation of interleukin-10 production (GO:0032733), positive regulation of interleukin-4 production (GO:0032753), T cell proliferation (GO:0042098), negative regulation of T cell proliferation (GO:0042130), homeostasis of number of cells within a tissue (GO:0048873), CD8-positive, alpha-beta T cell homeostasis (GO:0160165), T cell homeostasis (GO:0043029), regulation of T cell activation (GO:0050863)

GO Molecular Function (3): cytokine receptor activity (GO:0004896), interleukin-20 binding (GO:0042015), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of cytokine production	2
positive regulation of cytokine production	2
T cell activation	2
cytokine binding	2
type IV hypersensitivity	1
regulation of type IV hypersensitivity	1
negative regulation of T cell mediated immunity	1
negative regulation of hypersensitivity	1
inflammatory response	1
immune response	1
immune response-regulating signaling pathway	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
type II interferon production	1
regulation of type II interferon production	1
interleukin-2 production	1
regulation of interleukin-2 production	1
interleukin-10 production	1
regulation of interleukin-10 production	1
interleukin-4 production	1
regulation of interleukin-4 production	1
lymphocyte proliferation	1
T cell proliferation	1
regulation of T cell proliferation	1
negative regulation of lymphocyte proliferation	1
negative regulation of T cell activation	1
tissue homeostasis	1
homeostasis of number of cells	1
T cell homeostasis	1
lymphocyte homeostasis	1
regulation of lymphocyte activation	1
transmembrane signaling receptor activity	1
cytokine-mediated signaling pathway	1
immune receptor activity	1
binding	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1015 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL20RB	IL22RA1	Q8N6P7	999
IL20RB	IL24	Q13007	995
IL20RB	IL20RA	Q9UHF4	989
IL20RB	IL19	Q9UHD0	977
IL20RB	IL10RA	Q13651	910
IL20RB	IL26	Q9NPH9	896
IL20RB	IL22	Q9GZX6	744
IL20RB	IFNL1	Q8IU54	704
IL20RB	IL10	P22301	681
IL20RB	IFNL3	Q8IZI9	680
IL20RB	STAT3	P40763	604
IL20RB	IL10RB	Q08334	559
IL20RB	IL6	P05231	545
IL20RB	IL22RA2	Q969J5	541
IL20RB	IL17B	Q9UHF5	492

IntAct

19 interactions, top by confidence:

A	B	Type	Score
IL20RB	IL20	psi-mi:“MI:0915”(physical association)	0.600
IL20	IL20RB	psi-mi:“MI:0407”(direct interaction)	0.600
IL20	IL20RB	psi-mi:“MI:0915”(physical association)	0.600
IL20RB	IL19	psi-mi:“MI:0915”(physical association)	0.600
IL19	IL20RB	psi-mi:“MI:0407”(direct interaction)	0.600
IL19	IL20RB	psi-mi:“MI:0915”(physical association)	0.600
MAL	IL20RB	psi-mi:“MI:0915”(physical association)	0.560
IL20RB	B4GALT5	psi-mi:“MI:0914”(association)	0.530
IL20RA	IL20RB	psi-mi:“MI:0915”(physical association)	0.520
IL20RB	IL22RA1	psi-mi:“MI:0915”(physical association)	0.400
IL22RA1	IL20RB	psi-mi:“MI:0915”(physical association)	0.400
IL20RB	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
MAL	IL20RB	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (49): IFNGR1 (Affinity Capture-MS), MYADM (Affinity Capture-MS), B4GALT5 (Affinity Capture-MS), BSCL2 (Affinity Capture-MS), NMU (Affinity Capture-MS), CTDNEP1 (Affinity Capture-MS), ZDHHC9 (Affinity Capture-MS), NDFIP2 (Affinity Capture-MS), HLA-A (Affinity Capture-MS), POM121 (Affinity Capture-MS), DHRS7 (Affinity Capture-MS), FGFR1 (Affinity Capture-MS), NCR3LG1 (Affinity Capture-MS), C5orf15 (Affinity Capture-MS), TMEM59 (Affinity Capture-MS)

ESM2 similar proteins: K7NA32, K7NAJ3, O09030, O70458, O70535, P14753, P16310, P17181, P19235, P21183, P22272, P22273, P24055, P26955, P31785, P33896, P34902, P40190, P40223, P40321, P42701, P42702, P42703, P78552, Q00560, Q04790, Q07303, Q28589, Q5XNR9, Q60837, Q65Z14, Q6PHB0, Q6UXL0, Q764M8, Q7TNI4, Q80XF5, Q8K5B1, Q8MJS1, Q8NI17, Q95118

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
IL19	up-regulates	IL20RB	binding
IL20	up-regulates	IL20RB	binding
IL20RB	up-regulates	STAT3

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	36
Likely benign	4
Benign	1

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
523198	GRCh38/hg38 3q22.2-22.3(chr3:135423479-136961152)x1	Likely pathogenic

SpliceAI

1465 predictions. Top by Δscore:

Variant	Effect	Δscore
3:136946293:TCGGT:T	donor_loss	1.0000
3:136946294:CGGTA:C	donor_loss	1.0000
3:136946295:GGTA:G	donor_loss	1.0000
3:136946296:G:GG	donor_gain	1.0000
3:136946297:T:TC	donor_loss	1.0000
3:136948257:A:AG	acceptor_gain	1.0000
3:136948258:G:GA	acceptor_gain	1.0000
3:136948258:GCCA:G	acceptor_gain	1.0000
3:136948258:GCCAA:G	acceptor_gain	1.0000
3:136982159:GGGA:G	acceptor_gain	1.0000
3:136982351:G:GG	donor_gain	1.0000
3:136995408:TTCCA:T	acceptor_loss	1.0000
3:136995409:TCCA:T	acceptor_loss	1.0000
3:136995411:CAG:C	acceptor_loss	1.0000
3:136995413:GGA:G	acceptor_gain	1.0000
3:136995565:G:GG	donor_gain	1.0000
3:137010112:GAAA:G	acceptor_gain	1.0000
3:136948254:TTTA:T	acceptor_loss	0.9900
3:136948256:TA:T	acceptor_loss	0.9900
3:136948258:G:GT	acceptor_loss	0.9900
3:136948258:GC:G	acceptor_gain	0.9900
3:136948258:GCC:G	acceptor_gain	0.9900
3:136958199:CAG:C	donor_gain	0.9900
3:136958199:CAGG:C	donor_loss	0.9900
3:136958200:AG:A	donor_gain	0.9900
3:136958200:AGGTA:A	donor_loss	0.9900
3:136958201:GG:G	donor_gain	0.9900
3:136958202:G:GG	donor_gain	0.9900
3:136958202:GTAA:G	donor_loss	0.9900
3:136982158:AG:A	acceptor_gain	0.9900

AlphaMissense

2033 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:136980539:G:C	W54C	0.989
3:136980539:G:T	W54C	0.989
3:136980537:T:A	W54R	0.987
3:136980537:T:C	W54R	0.987
3:136982279:G:C	R112P	0.985
3:136982282:T:A	V113D	0.984
3:136980580:T:A	V68D	0.978
3:136982335:T:C	F131L	0.976
3:136982337:T:A	F131L	0.976
3:136982337:T:G	F131L	0.976
3:136982243:C:T	T100I	0.975
3:136989527:T:C	F165L	0.972
3:136989529:C:A	F165L	0.972
3:136989529:C:G	F165L	0.972
3:136980517:A:T	N47I	0.971
3:136980521:G:A	M48I	0.971
3:136980521:G:C	M48I	0.971
3:136980521:G:T	M48I	0.971
3:136982233:T:A	C97S	0.968
3:136982234:G:C	C97S	0.968
3:136980585:T:G	Y70D	0.965
3:136982316:G:C	W124C	0.965
3:136982316:G:T	W124C	0.965
3:136992052:A:C	S216R	0.965
3:136992054:C:A	S216R	0.965
3:136992054:C:G	S216R	0.965
3:136980518:C:A	N47K	0.964
3:136980518:C:G	N47K	0.964
3:136982193:G:C	W83C	0.964
3:136982193:G:T	W83C	0.964

dbSNP variants (sampled 300 via entrez): RS1000084834 (3:137004742 G>A), RS1000140701 (3:137007505 C>T), RS1000191817 (3:137007753 G>A), RS1000207122 (3:136992969 A>G), RS1000251920 (3:136971323 A>G,T), RS1000287113 (3:136958809 C>G), RS1000392742 (3:136957477 A>G), RS1000455567 (3:137001198 C>T), RS1000472503 (3:137008867 G>A), RS1000499011 (3:136977915 A>C), RS1000530114 (3:136960467 C>A,T), RS1000536684 (3:136991524 C>G,T), RS1000591042 (3:136973112 T>C), RS1000595145 (3:136959047 T>C), RS1000600269 (3:136992734 T>C)

Disease associations

OMIM: gene MIM:605621 | disease phenotypes: MIM:617635

GenCC curated gene-disease

Mondo (1): intellectual disability, autosomal dominant 47 (MONDO:0030912)

Orphanet (1): STAG1-related intellectual disability-facial dysmorphism-gastroesophageal reflux syndrome (Orphanet:502434)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

16 associations (top):

Study	Trait	p-value
GCST002202_4	Anxiety in major depressive disorder	7.000000e-06
GCST002318_119	Rheumatoid arthritis	9.000000e-10
GCST002541_4	Menarche (age at onset)	1.000000e-09
GCST004521_157	Autism spectrum disorder or schizophrenia	3.000000e-08
GCST005023_23	Initial pursuit acceleration	6.000000e-06
GCST006914_20	Sleep duration	1.000000e-08
GCST006914_26	Sleep duration	2.000000e-06
GCST006959_37	Rheumatoid arthritis	9.000000e-08
GCST008163_592	Height	3.000000e-06
GCST90002407_410	White blood cell count	4.000000e-09
GCST90020028_1722	Hip circumference adjusted for BMI	4.000000e-08
GCST90020028_1723	Hip circumference adjusted for BMI	5.000000e-09
GCST90020029_1358	Waist circumference adjusted for body mass index	4.000000e-10
GCST90020029_1359	Waist circumference adjusted for body mass index	2.000000e-10
GCST90020029_681	Waist circumference adjusted for body mass index	8.000000e-09
GCST90020029_707	Waist circumference adjusted for body mass index	1.000000e-08

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0008434	initial pursuit acceleration
EFO:0008039	BMI-adjusted hip circumference
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — IL-10 receptor family

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, decreases expression	6
entinostat	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
Cisplatin	affects expression, increases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Valproic Acid	affects cotreatment, increases expression	2
Cyclosporine	increases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
Asian ginseng	decreases expression, decreases reaction	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
propionaldehyde	increases expression	1
trichostatin A	increases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
cupric chloride	decreases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
CGP 52608	affects binding, increases reaction	1
chloropicrin	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2,2’,4,4’,5-brominated diphenyl ether	increases expression	1
ICG 001	increases expression	1
abrine	increases expression	1
palbociclib	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1

Cellosaurus cell lines

5 cell lines: 3 cancer cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7S4	Ubigene A-549 IL20RB KO	Cancer cell line	Male
CVCL_D8N5	Ubigene HCT 116 IL20RB KO	Cancer cell line	Male
CVCL_E0F1	Ubigene HeLa IL20RB KO	Cancer cell line	Female
CVCL_E8EE	HEK-Blue IL-19/IL-20	Transformed cell line	Female
CVCL_E8EF	HEK-Blue IL-20	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.